Rare disease biotech Aldeyra Therapeutics increases shares offered, deal size is now $25 million

Comment

Shutterstock photo

Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, raised the proposed deal size for its upcoming IPO on Friday. The Burlington, MA-based company now plans to raise $25 million by offering approximately 2.3 million shares (up from 2.0 million) at a price range of $10 to $12. At the midpoint of the revised range, it is expected to raise 14% greater proceeds than previously anticipated.

Aldeyra Therapeutics, which was founded in 2004, plans to list on the NASDAQ under the symbol ALDX. Aldeyra Therapeutics initially filed confidentially on December 4, 2013. Aegis Capital Corp. are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com